GASTRIC CANCER

This early-stage study tested a new drug called CUE-102 in 42 adults with certain advanced cancers (colorectal, stomach, pancreatic, or ovarian) that had returned or spread and were no longer responding to standard treatments. The goal was to find a safe dose and see if the drug …

This large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery could improve outcomes for people with stomach or gastroesophageal junction cancer. Over 1,000 participants were randomly assigned to r…

This study tested a new treatment for stomach cancer that has spread to the lining of the abdomen. It combined standard IV chemotherapy with a procedure called PIPAC, which sprays chemotherapy directly into the abdomen as a mist. The goal was to see if this combination was practi…

This study tested whether a longer intestinal bypass during stomach removal surgery helps control type 2 diabetes better than the standard method. It included 94 adults with early-stage gastric cancer and diabetes. The goal was to see if more patients could achieve normal blood s…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, or breast cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, but res…

This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer or other cancers linked to a CDH1 gene mutation. The goal was to see if the treatment could shrink tumors and to check for side effects. While both drugs had…

This early-stage study tested a new treatment called VE800 combined with the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The main goal was to see if the combination is safe and whether it can shrink …

This early-phase study tested a new drug called cabotamig in 33 adults with advanced gastrointestinal cancers (like colon, stomach, liver, or pancreatic cancer) that had stopped responding to standard treatments. The drug works by attaching to a marker on cancer cells and helping…

This early-phase trial tested a new treatment for people with advanced cancers (like pancreatic, stomach, or colon cancer) that have a specific genetic change called KRAS G12D. Doctors took participants' own white blood cells, modified them in a lab to better recognize and attack…

This study tested a new computer-based tool that helps doctors adjust chemotherapy doses for people with cancers of the digestive system (like colorectal or stomach cancer). The goal was to reduce unplanned treatment delays caused by low blood cell counts. 52 adults receiving FOL…

This early-phase study tested an experimental drug called SHR-A1811 in 101 people with advanced stomach or colorectal cancers that have a specific marker (HER2). The goal was to find a safe dose and see if the drug can shrink tumors. Participants had cancers that stopped respondi…

This study tested a combination of chemotherapy (CAPOX) and two targeted antibodies (trastuzumab and bevacizumab) in 37 adults with HER2-positive stomach or esophagus cancer that had spread. The goal was to see if the combo could shrink tumors and control the disease. While not a…

This study tested a new drug called SAR444245 (THOR-707) combined with other cancer treatments in 138 adults with advanced or metastatic gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancers. The goal was to see if the combination could shrink tum…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers that had stopped responding to standard treatments. The cancers included triple-negative breast, ovarian, gastric, colorectal, glioblastoma, biliary tract, and pancreat…

This study tested a drug called savolitinib in 110 adults with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific gene change (MET amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants received savoli…

This study tested a new drug (FLX475) combined with an immunotherapy (pembrolizumab) in 20 people with advanced or metastatic stomach cancer who had already tried other treatments. The goal was to see if the combination could shrink tumors. Participants were split into two groups…

This study tested a drug called PRL3-ZUMAB in 14 adults with advanced solid tumors (including stomach and liver cancers) that had stopped responding to standard therapies. The drug was given intravenously every two weeks. The goal was to see if it could shrink tumors or stop them…

This study looked at a biosimilar version of trastuzumab (a targeted cancer drug) in 8 people with advanced or recurrent HER2-positive stomach cancer. The goal was to confirm the drug's safety and how well it worked in real-world use. Researchers tracked side effects and tumor re…

This study looked at whether a specific chemotherapy and radiation plan is feasible for people with gastric cancer. 63 patients received treatment either before or after surgery to remove their stomach tumor. The goal was to see if the treatment plan could be completed without ma…

This study tested a new combination of two drugs, GEN-001 and avelumab, in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior treatments. The goal was to see if the combination could shrink tumors or slow cancer growth…

This early-phase study tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, or lung cancer) that had stopped responding to standard treatments. The drug is a nanoparticle version of SN-38, a chemotherapy agent, given by IV on days 1 a…

This study tested whether adding two drugs (camrelizumab and apatinib) to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. About 885 adults who had not received prior treatment for advanced disease took part. The goal was t…

This study tested whether combining two drugs, TAS 102 and ramucirumab, is safe and works for people with advanced stomach or gastroesophageal junction cancer that no longer responds to other treatments. 23 participants were enrolled. The goal was to see how long they lived and h…

This early-phase study tested a new treatment using specially engineered immune cells (CAR-NK cells) from donated cord blood to target a protein called Claudin18.2 found on some stomach and pancreatic cancer cells. Ten adults with advanced cancer who had no other treatment option…

This study tested a combination of two drugs, telatinib and Keytruda, in 16 people with advanced stomach, gastroesophageal junction, or liver cancer. The goal was to see if the combo could slow cancer growth or improve survival. Participants had already tried other treatments wit…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with stomach or gastroesophageal junction cancer. About 120 adults in China received either the drug combo or a placebo plus chemo before and after surgery. The goal was to…

This study looked at how a type of PET/CT scan (using 18F-FDG) can help doctors more accurately diagnose, stage, and track stomach cancer. Researchers studied 50 patients with confirmed stomach cancer to see if the scan could find tumors and check how well treatment is working. T…

This study tested a new imaging agent called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The goal was to see if this PET scan could better detect cancer cells compared to standard methods. Resear…

This study tested a training program for doctors using a special microscope called confocal laser endomicroscopy (CLE) during stomach exams. The goal was to help them better identify cancerous and precancerous lesions in the stomach. 147 patients took part, and the researchers me…

This study tested a new type of PET scan (FAPI) in 20 people with stomach or gastro-esophageal junction cancer to see if it can more accurately determine the cancer stage than standard scans. Participants received the FAPI scan alongside usual imaging before and after chemotherap…

This study compared two surgical methods for stomach cancer: laparoscopic (keyhole) surgery and open surgery. The goal was to see if keyhole surgery leads to a shorter hospital stay and fewer complications. 210 adults with resectable stomach cancer took part. Results will help do…

This study tested a new way to predict whether immunotherapy before surgery will work for people with stomach or rectal cancer. Researchers used epigenetics (how genes are turned on or off) to build a prediction model. 189 participants were involved, and the goal was to see if th…

This study tested a new automated method to grow cancer cells from patients with metastatic cancers (like prostate, breast, lung) inside chicken eggs. The goal was to see if this system could successfully grow tumors from patient samples, which could help doctors study cancer and…

This study tested a risk scoring model to predict if stomach cancer will spread to the liver after surgery. Researchers followed 120 patients who had their stomach cancer removed to see how well the model worked. The goal is to help doctors identify high-risk patients and plan be…

This study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer who received nivolumab as their first treatment. The goal was to see how well the drug worked in real-world settings and how it was used. No new treatments w…

This study tested over 1,000 people in rural Bhutan for H. pylori bacteria and early signs of stomach cancer. Researchers used blood tests and, for high-risk groups, endoscopy to understand infection rates and cancer risk. The goal was to gather baseline data to help launch a nat…

This study tested a risk scoring model that predicts whether stomach cancer has spread to nearby lymph nodes before surgery. Researchers collected data from 120 patients who had their stomach cancer removed to see how well the model works. The goal is to help doctors plan better …

This study follows over 32,000 people from Linxian, China, who took part in vitamin and mineral trials in the 1980s. Researchers want to see if the supplements had long-term effects on cancer and overall death rates. They also collect blood samples and health surveys to learn mor…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…